With 90 Percent of Digene Shares Tendered, Qiagen Preps to Close $1.6B Acquisition | GenomeWeb
NEW YORK (GenomeWeb News) - Qiagen said its offer to buy all of Digene's outstanding shares expired on Friday night, and that it plans to continue with the acquisition by accepting tendered shares making up more than 90 percent of Digene's stock.
Qiagen said it will complete the $1.6 billion deal, without the approval of Digene's stockholders, after the acceptance of the shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.